The rule, which became effective Nov. 30, 2020, is aimed at reducing costs by allowing the importation of certain prescription drugs from Canada.
The new guidance explains how importers can obtain supplies from authorized Section 804 Importation Programs (SIP). The supply chain for each drug must be limited to three entities: one manufacturer, one foreign seller and one importer. Foreign sellers must be licensed to wholesale drugs by Health Canada and registered with the FDA.
The agency retains the authority to not authorize or discontinue a SIP if a foreign seller does not meet all requirements.
The guidance also outlines testing and labeling requirements for all imported drugs.
Read the full guidance here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
